Skip to main content

Table 1 Patient characteristics

From: Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

 

No. of patients (n = 45)

No.

%

Age at diagnosis, years

 Median

60 (range: 32 to 81)

Sex

 Male

30

 

66.7

 Female

15

 

33.3

Primary tumor location

 Gastroesophageal junction/fundus

4

 

8.9

 Body

8

 

17.8

 Antrum

22

 

48.9

 Diffuse

11

 

24.4

Primary tumor tissue for HER2 assessment

 Endoscopic biopsy

38

 

84.4

 Surgical resection

7

 

15.6

Lauren classification

 Intestinal

21

 

46.7

 Diffuse

23

 

51.1

 Mixed

1

 

2.2

WHO classification

 Tubular adenocarcinoma

  Well differentiated

1

 

2.2

  Moderately differentiated

18

 

40.0

  Poorly differentiated

13

 

28.9

 Mucinous carcinoma

1

 

2.2

 Poorly cohesive carcinoma

11

 

24.5

 Mixed adenocarcinoma

1

 

2.2

Cell block of malignant effusion (n = 71)

 Sample type

   

  Ascitic fluid

64

 

90.1

  Pleural fluid

7

 

9.9

 Cellularity

   

  High (> 10% tumor cells)

40

 

56.3

  Low (≤10% tumor cells)

31

 

43.7

 Time of effusion sample collection

  At the diagnosis of metastatic disease before chemotherapy

23

 

32.4

  During or after palliative chemotherapy

48

 

67.6

  1. HER2, human epidermal growth factor receptor 2; WHO, World Health Organization